Illumina Inc. announced it has formed collaborative partnerships with AstraZeneca, Janssen Biotech Inc. and Sanofi to develop a universal next-generation sequencing oncology test system.

The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multigene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.

“The transition to patient-centered companion therapeutics marks a new era for oncology, and we are pleased to see pharmaceutical companies working with Illumina on a universal platform to bring life-saving treatments through their development pipelines,” said Ellen V. Sigal, Ph.D., Chair and Founder of Friends of Cancer Research. “This is the type of collaboration that will make real progress for patients.”

Illumina (Nasdaq: ILMN) is a developer, manufacturer and marketer of life science tools and systems of genetic analysis.